Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition.

Blood advances - 10 May 2022

Maslah Nabih, Verger Emmanuelle, Giraudier Stéphane, Chea Mathias, Hoffman Ronald, Mascarenhas John, Cassinat Bruno, Kiladjian Jean-Jacques

Abstract excerpt

The mechanisms of transformation of chronic myeloproliferative neoplasms (MPN) to leukemia are largely unknown, but TP53 mutations acquisition is considered a key event in this process. p53 is a main tumor suppressor, but mutations in this protein per se do not confer a proliferative advantage to the cells, and a selection process is needed for the expansion of mutant clones. MDM2 inhibitors may rescue normal p53...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Clone Cells

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mutation

Share to Myeloproliferative Disorders

Share to Proto-Oncogene Proteins c-mdm2

Share to Single-Cell Analysis

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 35030630
DOI: 10.1182/bloodadvances.2021005867
PMCID: PMC9092407

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition.PMID 35030630Read ↗

Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape.Semantic proximity Read ↗

Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia.Semantic proximity Read ↗

Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status.Semantic proximity Read ↗

JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasmsSemantic proximity Read ↗

Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.Semantic proximity Read ↗

<i>TP53</i> mutations and drug sensitivity in acute myeloid leukaemia cells with acquired MDM2 inhibitor resistanceSemantic proximity Read ↗

Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlinSemantic proximity Read ↗

Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia.Semantic proximity Read ↗

MDM2 inhibition is associated with the emergence of TP53-altered clonal hematopoiesisSemantic proximity Read ↗

Pseudo-mutant P53 is a unique phenotype of DNMT3A-mutated pre-leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.